1,208
Participants
Start Date
August 19, 2022
Primary Completion Date
January 23, 2023
Study Completion Date
March 21, 2023
SIM0417
dose of 750 mg SIM0417 with 100 mg ritonavir.
Placebo
Placebo (tablet)
Hefei First People's Hospital, Hefei
Beijing Ditan Hospital Captial Medical University, Beijing
Chongqing Public Health Medical Center, Chongqing
The First Affiliated Hospital of Xiamen University, Xiamen
Guangzhou Eighth People's Hospital Guangzhou Medical University, Guangzhou
Maoming People's Hospital, Maoming
Qingyuan People's Hospital, Qingyuan
The Third People's Hospital of Shenzhen, Shenzhen
Central People's Hospital of Zhanjiang, Zhanjiang
The Fifth Affiliated Hospital Sun Yat-Sen University, Zhuhai
GuiZhou Province People's Hospital, Guiyang
Haikou people's Hospital, Haikou
Hainan Third People's Hospital, Sanya
Mudanjiang Kangan Hospital, Mudanjiang
Wuhan Jinyintan Hospital, Wuhan
The First Hospital of Changsha, Changsha
The Second Hospital of Nanjing, Nanjing
ZhongDa Hospital SouthEast University, Nanjing
The Fifth People's Hospital of Suzhou, Suzhou
Taizhou People's Hospital, Taizhou
Wuxi No.5 People's Hospital, Wuxi
Xuzhou Infectious Disease Hospital, Xuzhou
Subei People's Hospital of Jiangsu province, Yangzhou
The Third People's Hospital of Zhenjiang, Zhenjiang
The First Affiliated Hospital of Nanchang University, Nanchang
The Sixth People's Hospital of ShenYang, Shenyang
Shandong Public Health Clinical Center, Jinan
Shanghai Public Health Clinical Center, Shanghai
Public health clinical center of Chengdu, Chengdu
Suining Central Hospital, Suining
Tianjin first center hospital, Tianjin
Affliated Hangzhou XiXi Hospital Zhejiang University School of Medicine, Hangzhou
Huzhou Central Hospital, Huzhou
HwaMei Hospital University of Chinese Academy of Sciences, Ningbo
Wenzhou Central Hospital, Wenzhou
Lead Sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
INDUSTRY